Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Flora Growth Corp. (NASDAQ: FLGC) Acquisition of Franchise Global Health Completed, Rapid Jump in Potential for European Cannabis Sales

  • International cannabis operator Flora Growth Corp. is rapidly expanding its global footprint and Colombia-based international supply chain thanks to strategic acquisitions during the past several months
  • Flora’s most recent acquisition was concluded just before Christmas on finalization of an agreement with multi-national operator Franchise Global Health Inc. that strengthens Flora’s position in Europe
  • Franchise Global Health (“FGH”) serves 1,200 pharmacies in Germany, which the companies regard as the doorway to the rest of Europe, and it also has a footprint in Portugal and Denmark, while Flora Growth has completed exports to Switzerland and the Czech Republic
  • Flora reported a 604 percent YOY increase in revenues for the first half of the year and recently added an increase of 414 percent YOY for the Q3 period

Cannabis cultivator and global distributor Flora Growth (NASDAQ: FLGC) is entering the new year with its latest acquisition completed, opening the way for accelerated expansion into Europe’s marketplace.

Franchise Global Health Inc. (TSX.V: FGH) announced Dec. 23 that it had completed arrangements for Flora Growth to acquire its issued and outstanding shares, and that the former holders of common shares of Franchise Global Health would be delisted from the TSX Venture Exchange on or about Dec. 28 as the company ends its public reporting obligations (https://cnw.fm/UmzJs).

Franchise Global Health Inc. serves 1,200 pharmacies in Germany through its wholly owned subsidiaries ACA Muller and Phatebo, and the company’s acquisition by Flora Growth will provide FGH with important cannabis supply chain security, while Flora will be able to build on the new inroad to the German market and launch farther into Europe from there.

“Our full focus is on Germany,” FGH CEO Clifford Starke said during an October webcast about the agreement. “Our strong position is on the distribution front. … Which, if this cannabis market is going to come to life, which we all believe so, … we’re extremely well positioned to go past Germany into the rest of Europe. It’s very important to understand that 75 to 80 percent of the sales in Europe are accounted in Germany.”

Flora has already exported its first high-CBD dried cannabis flower products from Colombia to Switzerland and the Czech Republic. Subsidiary JustCBD, acquired by Flora earlier in the year, registered 79 products with the United Kingdom’s novel foods standards agency as well.

Flora operates its Cosechemos cultivation, processing, extraction and isolation facility in Colombia, a country with prime growing conditions that has undergone a renaissance in cannabis cultivation during the past few years as the national government has achieved a framework for legalizing the export of select cannabis products.

Flora reported a 604 percent increase YOY in its H1 revenues, and its Q3 financials showed similar momentum as revenue for the three-month period ended Sept. 30 came in at $10.8 million, an increase of 414 percent year over year accompanied by a 703 percent YOY growth in gross profit (https://cnw.fm/uNae5).

In addition to FGH’s early mover advantage in Germany, the company has a footprint in Portugal and Denmark, offering further potential for Flora’s European market ambitions (https://cnw.fm/g6T2C).

For more information, visit the company’s website at www.FloraGrowth.com.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — NORML Analysis Reveals Significant Uptick in Cannabis Research in 2022

Researchers have been busy, publishing more than 4,300 scientific papers on marijuana, making 2022’s tally a new record for annual cannabis research published. It is said that cannabis and its components are the most understudied, yet they have attracted plenty of researchers’ attention in current times. With cannabis being a federally illicit substance, studying it would be most agreeable to most people, especially given that more states are legalizing marijuana in one form or another.

Largely, a societal misconception has it that cannabis is not extensively studied hence a lot of myths carry the day as far as policy reforms are concerned.

An analysis targeting the federal Pubmed.gov site shows that more than 4,300 scientific research publications have been made available worldwide targeting cannabis and its derivatives. This number of articles exceeds last year’s 4,200 articles.

The claims that marijuana has not been amply studied falls flat when such a sizeable annual tally of research papers is considered, and interest in studying cannabis has sharply increased recently even as we try to understand the plant and its potent components, including pharmacokinetics and pharmacodynamics, as well as its effects on the user and society at large, according to a blog post penned by Paul Armentano, NORML’s deputy director.

Armentano added that politicians need to cease assessing cannabis negatively and engage in evidence-based discussions about cannabis and policies that bring to light more objective or factual information about the plant. Advocates looking to support the marijuana bill have merged with prohibitionists in support of extensive cannabis research. This is emphasized due to President Joseph Biden assenting to a standalone bill streamlining marijuana/cannabis studies.

Separately, the House and Senate passed a similar bill on cannabis research in late 2020 though none of those bills made it to President Trump’s desk for approval by the end of his tenure in office.  Researchers in Congress have released a report detailing challenges encountered because of the prohibition from federal governments and the possible options available to the lawmakers to address.

The Drug Enforcement Administration (DEA) has also stepped in to approve new marijuana growers to boost the supply for these studies. Finally, the National Institute on Drug Abuse published an appeal for applications from authorized growers as new contractors to supply the plant to the agency for research purposes.

Biden signed a large-scale framework legislation that contained provisions which would allow researchers to study the real plant purchased by consumers from state-licensed suppliers instead of using government-grown cannabis only.

NIDA director Nora Volkow has admitted that scientists have been limited in getting research data for the study of cannabis and it would be good to establish a body to initiate a policy change that allows access to marijuana products from the state-legal outlets.

As more research finds its way into the public domain, perceptions are likely to undergo a dramatic shift, and it may not be long before many people take up the legal cultivation of cannabis indoors using the latest compact indoor grow equipment from manufacturers such as Advanced Container Technologies Inc. (OTC: ACTX).

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Google Lifts Ban on Ads for Hemp, CBD Products in Some US Jurisdictions

Google plans to lift a ban on advertising certain CBD and hemp products in some parts of America in January 2023. In an announcement made last week, the global technology company confirmed that it would permit the advertising of cannabis products in Puerto Rico, Colorado and California by updating its list of dangerous medicines products, services and healthcare.

The company stated that the FDA’s approval of hemp-sourced CBD products containing 0.3% or less THC level as well as pharmaceuticals containing CBD meant that the products could now be advertised in the aforementioned jurisdictions. Google added that while CBD would be deleted from its list of banned pharmaceuticals and supplements, other advertisements that promoted other CBD-infused products, such as inhalants, food additives and supplements were still banned.

It remains unclear why the internet giant is restricting the change in policy in California, Colorado and Puerto Rico, especially since hemp and its derivatives are federally legal and their products are marketed throughout the country.

Google is working with LegitScript to certify marijuana products for advertising eligibility. The company explained that in the U.S., only topical CBD products certified by the company could be promoted on the site, noting that certification required that companies seeking to advertise their products present samples of the products for testing to ensure they comply with the current limit for THC. Additionally, companies would need to provide a certificate of analysis from a third party.

Scott Roth, CEO of LegitScript, stated in a press release that the company’s seal on websites or products showed that companies operated safely and transparently. He noted that it was important to ensure consumers that the CBD products they were buying had been vetted properly, especially in an industry that was still experiencing issues with products being substandard, tainted or even illegal.

The notice issued by Google also highlights that pharmaceuticals approved by the FDA as well as LegitScript-certified advertisers will also need to be certified by Google before they can run their ads. Google notes that advertisers can request certification beginning Jan. 20, 2023.

The internet giant’s shift may positively influence the hemp industry, particularly if it’s stretched to cover all territories and states.

A few years ago, Google received criticism after its announcement on the banning of cannabis products from Google Play. It seems to have yielded, however, as delivery services such as Eaze can be found on the app store.

As more tech platforms ease their restrictions on advertising various products derived from hemp, entities such as Flora Growth Corp. (NASDAQ: FLGC) are likely to have more ways to reach potential clients, thereby boosting their growth strategies.

NOTE TO INVESTORS: The latest news and updates relating to Flora Growth Corp. (NASDAQ: FLGC) are available in the company’s newsroom at https://cnw.fm/FLGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Releases Status Update on Commercial Cannabis Export Business

Flora Growth (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is reporting on its commercial cannabis operations out of Colombia. According to the status update, the company exported an estimated 1,000 kilograms of commercial cannabis dry flower and derivatives to Europe and the United States in the fourth quarter of 2022; the company also received an updated cannabis export and production quota from the Colombian government, which included the addition of four additional proprietary genetics and increased production for domestic medical markets. The company noted that this activity is a result of the full commercialization of the Cosechemos farm and Flora Lab One facility in Bucaramanga, Colombia. “As the largest cultivator of commercial cannabis in Colombia, our ability to activate our farm and distribute products is nearly unmatched,” said Flora Growth chair and CEO Luis Merchan in the press release. “With the acquisition of Franchise Global Health completed just last week, we now have direct lines of distribution to Germany and the rest of Europe.”

To view the full press release, visit https://cnw.fm/s6I06

About Flora Growth Corp.

Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands designed to deliver the most compelling customer experiences in the world, one community at a time. As the operator of one of the largest outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its commercial, house of brands and life sciences divisions.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Schumer Promises to Fight for Federal Cannabis Decriminalization in 2023

After reformers encountered several defeats in December, Senate Majority Leader Chuck Schumer has pledged to continue working toward decriminalizing marijuana on a federal level next year. Schumer gave a speech in the Senate in which he praised the efforts of Reggie Babin, a senior staffer who has been leading the charge for marijuana policy reform legislation. He promised to carry on with Babin’s work and legacy, mentioning a few things that Babin had wished to accomplish, such as aiding in the decriminalization of marijuana.

Even though Schumer, Senator Cory Booker (D-NJ) and Senator Ron Wyden produced a comprehensive cannabis legalization measure in July, analysts say it was obvious that the extensive legislation lacked the support necessary to pass the Senate with 60 votes.

Due to this, Schumer has moved to complete a set of more modest reforms, with the banking and decriminalization of cannabis as their focal points. Advocates had anticipated that the reform would be tacked onto important defense or funding bills that were required to advance before the session ended. However, that did not occur, largely because backers ran into opposition from Senate Minority leader Mitch McConnell (R-KY) and other Republicans.

In late December, Representative Ed Perlmutter, a Democrat from Colorado and the lead sponsor of SAFE Banking, tabled an amendment modifying the omnibus spending bill to incorporate the reforms. However, Perlmutter didn’t compel putting the matter to a vote; it was mostly made as a show of support prior to his resignation from Congress.

A Senate insider recently said that Schumer was attempting to incorporate the marijuana banking language into the country’s spending bill at the last minute but was unable to come to an agreement. He said the issue would have to wait until the new Congress takes office, in which the House will be under Republican control.

Obviously, discussions about including new provisions in the bill were delicate, and reform on drug policy suffered as a result until a final consensus position was reached. Along with not mentioning SAFE Plus or SAFE Banking, the law also excluded a number of other reform ideas that were added to budget bills which were previously enacted by the Senate and House.

Another significant defeat for proponents is that this bill keeps a clause that bars the country’s capital from setting up a controlled cannabis trade system.

Sherrod Brown, the chair of Senate’s Banking Committee, indicated that there’s a high chance  cannabis banking would come up in 2023. Nevertheless, a staff member said early in December that he would still be open to including it in the spending bill if it contained more comprehensive provisions.

The Financial Services Committee head in the upcoming Congress, Representative Patrick McHenry (R-NC), has stated that he agrees that the matter should be handled after the “lame duck” is over. Although the congressman declared that he continues to oppose SAFE Banking, he left the door open to backing it on condition that his Republican colleagues embrace it too.

The goings on in the upcoming Congress are likely to be of key interest to companies such as India Globalization Capital Inc. (NYSE America: IGC) because any policy changes could have a profound impact upon the trajectory of the marijuana industry.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — SAFE Banking Act Sponsor Retires from Congress

Representative Ed Perlmutter, who sponsored the Secure and Fair Enforcement Banking (SAFE) legislation, has retired from Congress. The congressman recently filed the text of his banking measure as an amendment to a large-scale appropriations bill. Senate Majority Leader Chuck Schumer had worked with the congressman to draft the Safe PLUS package. However, opposition from Senate Minority Leader Mitch McConnell and other Republicans made it hard for the amendments to be included in the National Defense Authorization Act.

Senator Cory Booker also assigned blame to McConnell, noting that his opposition to marijuana reform had influenced Republican members who would have otherwise been open to approving the spending bill containing SAFE banking language.

The recent amendment contained provisions to a pair of separate initiatives on gun rights for marijuana consumers and expungement of previous cannabis convictions. As one, the amendments made up a SAFE Plus compromise, which advocates expected would be included in the appropriations bill; the measure was still not approved.

It should be noted that the amendments comprised of virtually identical text to the corresponding standalone measures on each of these issues and did not include changes to the financial components as has been agreed upon by leaders in the Senate these last few weeks.

The congressman has in the past expressed his frustrations over the Senate’s failure to take up the SAFE Banking Act, even after it was approved by the House more than once. However, despite Perlmutter arguing that excluding marijuana reform from the appropriations bill was a glaring omission, he didn’t force a vote on the issue and instead noted that there wasn’t a lot of freedom to make big amendments and send the bill back to Senate, especially since preventing it from being enacted in short order could possibly cause a government shutdown.

The congressman then observed that senators played a game that ultimately allowed them to control what was included in the spending legislation.

Advocates are now looking to advance the reform next year, with Senate Banking Committee Chair Sherrod Brown signaling that marijuana banking would likely be an issue next year. A staffer revealed recently that Brown was open to the cannabis banking bill being passed through the funding bill if it contained broader provisions.

For his part, Representative Patrick McHenry also stated that a decision on the issue would need to be made, noting that while he remained opposed to the bill, the door was open to its advancement if that was the will of his Republican counterparts.

In the next Congress, McHenry will serve as the House Financial Services committee chair.

The failure to pass legislation allowing cannabis banking is a setback for the industry, but the existence of alternative funding sources offered by companies such as REZYFi Inc. provide a stop gap to access funds for expansion and normal operations.

NOTE TO INVESTORS: The latest news and updates relating to REZYFi Inc. are available in the company’s newsroom at https://cnw.fm/REZY

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Dosing Begins in Lexaria Bioscience Corp. (NASDAQ: LEXX) Human Clinical Study, Evaluating DehydraTECH(TM)-Nicotine Against Leading Nicotine Oral Pouch Brands

  • The 36-person human pharmacokinetic randomized, double-blind, cross-over study NIC-H22-1 will compare its patented DehydraTECH(TM)-nicotine to leading nicotine pouches On! and Zyn
  • The white pouch oral delivery of nicotine is thought to avoid harmful lung outcomes that smokers and vapers experience
  • The global nicotine pouch market was valued at $2.33 billion in 2020 and is expected to reach $21.84 billion by 2027, driven by an increase in the number of consumers seeking alternative forms of nicotine that do not involve lung exposure

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, announced that dosing has commenced for its human clinical nicotine study NIC-H22-1. The study is a 36-person human pharmacokinetic randomized, double-blind, cross-over study conducted on current cigarette smoking subjects. Each participant will visit the laboratory and be dosed three times over the coming weeks. Only one oral nicotine pouch will be administered and evaluated during each visit. Participants will either receive Lexaria’s patented DehydraTECH(TM)-nicotine, On! brand manufactured by Altria, or Zyn brand manufactured by Swedish Match during that time (https://cnw.fm/QLXXQ).

The objectives of the NIC-H22-1 study are to determine the quantity of nicotine in blood at various time points and vital-sign data collection of temperature, blood pressure, heart rate, and respiratory rate. The company also plans to collect subjective evaluations, including throat burn, user experience, gastrointestinal experience, and more.

The global nicotine pouches market was valued at $2.33 billion in 2020 and is expected to reach $21.84 billion by 2027, growing at a CAGR of 30.7% during the forecast period (https://cnw.fm/ndfl1). Key market growth factors include a growing interest in nicotine pouches among those trying to quit smoking and the increased interest of consumers looking for alternative forms of nicotine that do not involve lung exposure.

The oral nicotine pouch category has become one of the fastest-growing segments of the nicotine industry due in part to a 2019 determination by the U.S. Food and Drug Administration (“FDA”) that stated the potential for “reduced risk health outcomes” (https://cnw.fm/d20a5). The delivery method, in the white pouch format specifically, is thought to avoid harmful lung outcomes experienced by smokers and vapers because it involves absorption primarily through the buccal tissues of the mouth using purified nicotine that has been separated from the other harmful compounds found within the tobacco leaf.

Lexaria’s patented DehydraTECH(TM) technology is designed for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH(TM) increases effectiveness and improves how these ingredients enter the bloodstream. Benefits of DehydraTECH include:

  • Improved speed of onset, with effects felt in minutes
  • Increased bioavailability, with more of the drug delivered into the bloodstream
  • Increased brain absorption, with testing suggesting up to 10x improvement
  • Improved drug potency, with more of the ingested product made available in the bloodstream requiring lower dosages

Animal studies conducted by Lexaria have demonstrated a propensity for DehydraTECH(TM) technology to elevate the quantity of the drug delivered across the blood-brain barrier by as much as 1,900 percent, which has initiated new patent applications and has opened the possibility of improved drug delivery.

As of September 2022, Lexaria’s development of its patented DehydraTECH(TM) technology since 2014 has yielded over 50 pending patents in countries worldwide, along with 27 granted patents. Lexaria’s focused ongoing research and development efforts span several key segments, including tobacco, nicotine replacement, CBD, cardiovascular drugs, antivirals, epilepsy, human hormones, and PDE5 inhibitors.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Minnesota Medical Association Backs Statewide Drug Decriminalization

The Minnesota Medical Board has endorsed decriminalization of illicit drugs, low quantity possession expungements and promotion of harm-reduction projects. Approved this month, the recommendation is to remove criminal sanctions for possessing a negligible amount of illicit drugs or drug paraphernalia for personal use.

The board also asked for an administrative panel to be created to provide treatment advice and lawful penalties to petty offenders who are found in possession of drugs. This dual approach ensures the policy reduces harm, similar to the one at play in Portugal.

The board said it is urgent to increase investment for harm reduction and installation of programs for the treatment of patients with opioid disorders. The board also noted that freeing inmates currently imprisoned over low amount possession and expungement of a criminal record on an inmate were also important.

A private draft of the complete proposal states that the medical board didn’t accept penalties of a criminal nature for small quantity possession for personal use, but the board did note that civil punishments are acceptable if they trigger a benefit to the health of the population. There is negligible data to corroborate the usefulness of criminal punishment for substance abuse. It would seem that the penalty yields the opposite effect, bringing harm to the populace through convictions, incarcerations, arrests and criminal records among others.

This is the first time a medical board endorsed a policy for drug reform denoting a vibrant reflection of the wave of public opinion away from models of criminalization of substance use. This proposal might entice conversations of drug policy among lawmakers as they prepare for the 2023 session. The medical board is willing to educate policy makers on health harms arising from imposing harsh penalties for minor possession of drugs and how inefficient the criminal penalty is for such infractions.

This endorsement has been in the works for months, with the policy council within the medical board creating an “illicit drug harm reduction and decriminalization” work group, in which members surveyed weighty matters and were handed a comprehensive preview showing drug usage and trends of policies. Nationally, Americans support the decriminalization of drugs and support the operation of centers for overdose prevention where users can consume illicit drugs in a controlled, medically approved setting.

The state’s medical board has yet to approve the cannabis legalization proposal, though it is a priority to Minnesota Governor Tim Walz, who looks forward to its speedy passage next year given now that Democrats have majorities in the legislature.

As policies around marijuana ease in different jurisdictions, opportunities will eventually arise for adults to grow their own cannabis indoors using innovative equipment such as that manufactured by Advanced Container Technologies Inc. (OTC: ACTX) and other such entities.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Study Finds Marijuana Legalization Has Greater Impact on Arrests Than Decriminalization

Researchers from the University of California San Diego recently conducted a study on the impact of adult-use decriminalization and legalization of marijuana on possession arrests. They discovered that legalization was linked to a significant decrease in marijuana possession arrests among individuals in legal states that decriminalized the drug prior to legalizing it. This is in addition to observing that the reduction in arrests was considerably higher in states that had shifted to legalization from criminalization without decriminalizing marijuana.

For their study, the researchers obtained data on marijuana possession arrests from the Uniform Crime Reporting program, with a primary focus on data from 31 states in the period between 2010–2019. The researchers carried out an analysis of this data, noting that of all the states included, only nine had implemented legalization during the period of study. Four of the nine states had legalized marijuana before they decriminalized it while the remaining five had legalized the drug after decriminalization.

The researchers observed that cannabis possession arrests had declined by more than 76% in the four states that legalized the drug before they decriminalized it. This was quite high, especially in comparison to the 40% decrease in arrest rates recorded in the five states that legalized cannabis after decriminalizing it.

The researchers stated that their findings suggest that legalizing marijuana without decriminalization first substantially affected the decline in arrest rates than legalizing the drug after decriminalizing it. They then noted that legalization was also linked to a further decrease in arrest rates, even after a state decriminalized marijuana. The reduction in marijuana possession arrests among White and Black people after legalization confirms this.

While both White and Black people have similar rates of marijuana use, Black people are more than three times as likely to be arrested for marijuana possession compared to White people.

The researchers observed that states which legalized marijuana before decriminalizing it recorded an almost 78% reduction in arrest rates among Black adults and 74.6% among White individuals. These figures are very high, especially when compared to the 41% and 35% decline in arrest rates among White and Black individuals respectively in states that decriminalized marijuana before legalizing it.

In their report, the investigators note that while their research compares decriminalization and legalization of marijuana purely from the perspective of a decline in possession arrests, it has a number of limitations. These limitations include the fact that some of the data used may not be accurate and that the data obtained from the Uniform Crime Reporting program is entered on a voluntary basis.

The study’s findings were reported in the “Journal of American Medical Association.”

Advocates have often argued that ending prohibition and allowing licensed companies such as Flora Growth Corp. (NASDAQ: FLGC) to operate legally has far-reaching benefits, and this study highlights yet another way through which this is true.

NOTE TO INVESTORS: The latest news and updates relating to Flora Growth Corp. (NASDAQ: FLGC) are available in the company’s newsroom at https://cnw.fm/FLGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Kentucky Prepares to Implement Medical Cannabis Executive Order

Last month, Kentucky Governor Andy Beshear signed an executive order that would partly legalize the use of medical cannabis. The executive order, which goes into effect on Jan. 1, 2023, will permit individuals in the state who have been diagnosed with various conditions to use and possess cannabis they purchase legally in other states.

The state of Kentucky is one of the few remaining ones in the country where it is still illegal to purchase either recreational or medical cannabis. States bordering the Bluegrass state with legal medical cannabis programs include Indiana, Ohio, Tennessee, Virginia, West Virginia, Missouri and Illinois. Of these states, only Indiana and Tennessee allow nonresidents to buy medical cannabis.

Medical conditions eligible for medical marijuana in Kentucky include cancer, intractable seizures, epilepsy, Parkinson’s disease, amytrophic lateral sclerosis (ALS) or Lou Gehrig’s disease, hepatitis C, Crohn’s disease, muscular dystrophy, sickle cell anemia, multiple sclerosis, Huntington’s disease, PTSD, severe and chronic pain, severe arthritis, neuropathies, cachexia or wasting syndrome, intractable pain, glaucoma, HIV/AIDS and any other terminal illness. Patients will need to have valid written certification from their physicians to use or possess legally purchased cannabis. Their medical provider’s written certification should contain the name, phone number and address of the medical provider as well as the patient.

In addition, the certification should also include the medical provider’s license number, their medical diagnosis, the provider’s signature, a statement which shows a bonafide provider-patient relationship and the date. The order stipulates that individuals will not be allowed to possess more than eight ounces of cannabis at any given time within the Bluegrass state. Individuals are also advised to keep the receipt showing when and where the drug was bought.

The total number of states that have legalized the use of recreational marijuana in the country will soon be 21, following Maryland and Missouri’s success on their general election ballot measures. The state of Missouri legalized the possession of recreational cannabis on Dec. 8, 2022. However, legal sales are not expected to begin until state regulations are finalized.

Virginia, which also borders Kentucky, also legalized recreational cannabis possession last year. The state has yet to launch its legal markets. As a result, residents of Kentucky will only be able to purchase recreational cannabis legally in bordering Illinois, whenever this will be permitted. Starting in 2023, however, Kentuckians will be able to buy recreational cannabis legally in Michigan.

This growing medical use of cannabis is also motivating many companies such as India Globalization Capital Inc. (NYSE American: IGC) to go a step further and develop cannabinoid-derived formulations which, once FDA approved, could be available through the hospital system.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.